The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population - PubMed (original) (raw)
The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population
Raxitkumar Jinjuvadia et al. J Clin Gastroenterol. 2017 Feb.
Abstract
Background: Prevalence of nonalcoholic fatty liver disease (NAFLD) and rate of advanced fibrosis among individuals with metabolic syndrome (MetS) and its individual metabolic abnormalities needs better understanding in the United States population. We aim to study these by using a large United States population database, the Third National Health and Nutrition Examination Survey (NHANES III).
Methods: A total of 11,674 individuals were included in our study cohort. NAFLD was defined as presence of moderate to severe hepatic steatosis on liver ultrasound in absence of viral hepatitis, significant alcohol use, elevated transferrin level, and medication use leading to hepatic steatosis. Advanced fibrosis among those with NAFLD was determined using noninvasive method, the NAFLD fibrosis score. MetS was defined based on the National Cholesterol Education Program Adult Treatment Panel III definition.
Results: The prevalence of NAFLD among included study cohort was 18.2% (95% confidence interval, 16.5-19.9). Individuals with metabolic abnormalities demonstrated higher prevalence (MetS, 43.2%; increased waist circumference, 31.2%; impaired fasting glucose/diabetes, 41.2%; high triglyceride level, 34.7%; low high-density lipoprotein, 27.8%; high blood pressure, 29.2%). The individuals with MetS had significantly higher NAFLD prevalence compared with controls (adjusted odds ratio, 11.5; 95% confidence interval, 8.9-14.7). The severity of hepatic steatosis was also noted to increase with higher number of metabolic abnormalities. Among individual metabolic abnormalities, increased waist circumference, impaired fasting glucose/diabetes, high triglyceride, and low high-density lipoprotein levels were found to be independently associated with NAFLD. Individuals with impaired fasting glucose/diabetes and those with 5 metabolic abnormalities had higher rate of advanced fibrosis (18.6% and 30.3%, respectively). Prevalence of NAFLD among individuals without any metabolic abnormality was 6.1%.
Conclusion: Prevalence of NAFLD and rate of advanced fibrosis are significantly high among individuals with metabolic abnormalities.
Conflict of interest statement
None. The views expressed in this article are those of the authors and do not represent those of the Department of Veterans Affairs or the United States government
Figures
Figure 1
Number of metabolic abnormalities and severity of hepatic steatosis
Figure 2
Severity of hepatic steatosis in metabolic abnormalities and controls Abbreviations: MetS – metabolic syndrome, WC – waist circumference, IFG – impaired fasting glucose, DM – diabetes, HDL – high density lipoprotein, BP – blood pressure
References
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. - PubMed
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. - PubMed
- Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578–584. - PubMed
- Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–692. - PubMed
- Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. - PubMed
MeSH terms
Substances
Grants and funding
- I01 CX000361/CX/CSRD VA/United States
- K08 AA016570/AA/NIAAA NIH HHS/United States
- R01 AA018389/AA/NIAAA NIH HHS/United States
- U01 AA018389/AA/NIAAA NIH HHS/United States
- U01 AA021840/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical